Role of CathWorks FFRangio for the Assessment of Coronary Artery Disease Now Reinforced by SCAI Expert Opinion

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

CathWorks

More Like This

PR Newswire associated0

CathWorks Announces Key Events for TCT 2025

PR Newswire associated0

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

PR Newswire associated0

CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full Launch of Co-promotion

PR Newswire associated0

CathWorks Announces Key Events for EuroPCR 2025

PR Newswire associated0

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PR Newswire associated0

MedHub-AI and Terumo partner to market AI-based FFR in Japan

PR Newswire associated0

Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial

PR Newswire associated0

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI